Juan Benezet-Mazuecos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Benezet-Mazuecos has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Jeff Healey
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
4 shared publications Julián Crosa
Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario La Luz, Madrid, España
4 shared publicationsÁlvaro Lozano
Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario La Luz, Madrid, España
4 shared publicationsÁngel Miracle
Unidad de Arritmias, Servicio de Cardiología, Hospital Universitario La Luz, Madrid, España
4 shared publications- Cecilia Linde
Heart, Vascular and Neurology Theme, Karolinska University Hospital , Stockholm
3 shared publications - Jens Cosedis Nielsen
Department of Cardiology, Aarhus University Hospital , Aarhus
3 shared publications
Latest Publications
- 13 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA
Aims: Heart failure (HF) and clinical atrial fibrillation are closely linked, but the relationship between device-detected subclinical atrial fibrillation (SCAF) and HF is unclear. We aimed to determine incidence and clinical risk factors for HF events among patients with SCAF. Methods: We included 3986 patients from the ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial. ARTESiA investigated the effect of apixaban versus aspirin for stroke prevention in patients with episodes of SCAF ≤24 hours. In this secondary analysis, we explored the number and duration of SCAF episodes at baseline as risk markers for HF hospitalization or HF-related death. SCAF progression was analysed as a time-dependent covariate and defined as the development of SCAF >24 hours or clinical atrial fibrillation. Results: Over a mean follow-up of 4.1 ± 1.7 years, SCAF progression was observed in 1244 patients (31%). Heart failure hospitalization or HF-related death occurred in 515 (13%) patients at a rate of 3.3 [95% confidence interval (CI) 3.1-3.6] per 100 person-years. A total of 172 HF-related events occurred after SCAF progression (7.2 events, 95% CI 6.2-8.3, per 100 PY). SCAF progression was an independent risk factor for HF hospitalization or HF-related death (hazard ratio 2.72, 95% CI 2.24-3.31). Conclusion: Heart failure hospitalization and HF-related death are common in patients with SCAF. Progression to longer SCAF episodes or clinical AF were associated with HF events, but episodes <24 h were not. These findings underscore the need for close surveillance of SCAF patients to detect complications and potentially improve outcomes.
- 13 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA
Aims: Heart failure (HF) and clinical atrial fibrillation are closely linked, but the relationship between device-detected subclinical atrial fibrillation (SCAF) and HF is unclear. We aimed to determine incidence and clinical risk factors for HF events among patients with SCAF. Methods: We included 3986 patients from the ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial. ARTESiA investigated the effect of apixaban versus aspirin for stroke prevention in patients with episodes of SCAF ≤24 hours. In this secondary analysis, we explored the number and duration of SCAF episodes at baseline as risk markers for HF hospitalization or HF-related death. SCAF progression was analysed as a time-dependent covariate and defined as the development of SCAF >24 hours or clinical atrial fibrillation. Results: Over a mean follow-up of 4.1 ± 1.7 years, SCAF progression was observed in 1244 patients (31%). Heart failure hospitalization or HF-related death occurred in 515 (13%) patients at a rate of 3.3 [95% confidence interval (CI) 3.1-3.6] per 100 person-years. A total of 172 HF-related events occurred after SCAF progression (7.2 events, 95% CI 6.2-8.3, per 100 PY). SCAF progression was an independent risk factor for HF hospitalization or HF-related death (hazard ratio 2.72, 95% CI 2.24-3.31). Conclusion: Heart failure hospitalization and HF-related death are common in patients with SCAF. Progression to longer SCAF episodes or clinical AF were associated with HF events, but episodes <24 h were not. These findings underscore the need for close surveillance of SCAF patients to detect complications and potentially improve outcomes.
- Open Access
- 18 March 2026
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 10 (1) , e85841
Short-Term Arrhythmia Prediction Using AI Based on Daily Data From Implantable Devices: Multicenter Prospective Observational Study
Background: Predictive medicine relies on algorithms to determine clinical treatments tailored to each patient’s individual characteristics. Predictive models based on artificial intelligence have shown promise in identifying atrial fibrillation episodes; however, they rarely focus on short-term dynamic prediction. Objective: This study aimed to evaluate the use of an artificial intelligence model and remote monitoring data extracted from pacemaker devices to predict the onset or worsening of arrhythmias in the short term. Methods: This was a multicenter prospective observational study in which data from 314 patients were analyzed. A total of 65,243 data sequences were collected, of which 55,532 (85.1%) were used to train the algorithm. This model used 31-day records to predict whether the number of arrhythmic episodes would increase, decrease, or remain the same in the following 14 days. Results: The sensitivity and specificity of the generated predictions were calculated from 9711 prediction-observation pairs. The global sensitivity was 66.4% (95% CI 64.3%-68.3%), and specificity was 77.4% (95% CI 76.4%-78.4%). For patients with baseline arrhythmia, sensitivity was 76.8% (95% CI 74.6%-78.8%), and specificity was 39.6% (95% CI 35.8%-43.5%). The prediction for patients with no baseline arrhythmia showed a sensitivity of 39% (95% CI 35.1%-43%) and a specificity of 81% (95% CI 80.0%-81.9%). The analysis for the patient subgroup without history of atrial fibrillation (232/314, 73.9%) yielded a 69% sensitivity (95% CI 66.5%-71.5%) and an 80% specificity (95% CI 79.3%-81.3%). Conclusions: This model was capable of predicting short-term increases or decreases in arrhythmic episodes with reasonable sensitivity and specificity using data collected through remote monitoring of implantable devices. The model’s performance is expected to improve progressively as more data samples become available, including demographic data and clinical records.
- 18 March 2026
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 10 (1) , e85841
Open AccessShort-Term Arrhythmia Prediction Using AI Based on Daily Data From Implantable Devices: Multicenter Prospective Observational Study
Background: Predictive medicine relies on algorithms to determine clinical treatments tailored to each patient’s individual characteristics. Predictive models based on artificial intelligence have shown promise in identifying atrial fibrillation episodes; however, they rarely focus on short-term dynamic prediction. Objective: This study aimed to evaluate the use of an artificial intelligence model and remote monitoring data extracted from pacemaker devices to predict the onset or worsening of arrhythmias in the short term. Methods: This was a multicenter prospective observational study in which data from 314 patients were analyzed. A total of 65,243 data sequences were collected, of which 55,532 (85.1%) were used to train the algorithm. This model used 31-day records to predict whether the number of arrhythmic episodes would increase, decrease, or remain the same in the following 14 days. Results: The sensitivity and specificity of the generated predictions were calculated from 9711 prediction-observation pairs. The global sensitivity was 66.4% (95% CI 64.3%-68.3%), and specificity was 77.4% (95% CI 76.4%-78.4%). For patients with baseline arrhythmia, sensitivity was 76.8% (95% CI 74.6%-78.8%), and specificity was 39.6% (95% CI 35.8%-43.5%). The prediction for patients with no baseline arrhythmia showed a sensitivity of 39% (95% CI 35.1%-43%) and a specificity of 81% (95% CI 80.0%-81.9%). The analysis for the patient subgroup without history of atrial fibrillation (232/314, 73.9%) yielded a 69% sensitivity (95% CI 66.5%-71.5%) and an 80% specificity (95% CI 79.3%-81.3%). Conclusions: This model was capable of predicting short-term increases or decreases in arrhythmic episodes with reasonable sensitivity and specificity using data collected through remote monitoring of implantable devices. The model’s performance is expected to improve progressively as more data samples become available, including demographic data and clinical records.
- Open Access
- 14 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
AI for the Prediction of Atrial Fibrillation or Atrial Tachycardia Episodes in Patients with Pacemakers (Preprint)
BACKGROUND Predictive medicine relies on algorithms to determine clinical treatments tailored to each patient’s individual characteristics. Predictive models based on AI have shown promise in identifying Atrial Fibrillation (AF) episodes; however, they rarely focus on short-term dynamic prediction. OBJECTIVE This study aims to evaluate the use of an AI model and remote monitoring data extracted from pacemaker devices to predict the onset or worsening of arrhythmias in the short term. METHODS This was an observational, prospective, multicenter study in which data from 314 patients were analyzed. A total of 65,243 data sequences were collected, of which 55,532 were used to train the algorithm. This model used 31-day records to predict whether the number of arrhythmic episodes increased, decreased, or remained the same in the following 14 days. RESULTS The sensitivity and specificity of the generated predictions were calculated from 9,711 prediction/observation pairs. The global sensitivity was 66.4% and specificity was 77.4%; with a sensitivity of 76.8% and specificity of 39.6% in patients with baseline arrhythmia; and a sensitivity of 39% and a specificity of 81% in patients without baseline arrhythmia. The analysis for the patient subgroup without prior history of AF yielded a 69% sensitivity and an 80% specificity. CONCLUSIONS This model was capable of predicting short-term increases or decreases in arrhythmic episodes with reasonable sensitivity and specificity, using data collected through remote monitoring of implantable devices. The model’s performance is expected to improve progressively as more data samples become available, including demographic and clinical records. CLINICALTRIAL Trial code: IA-Pacing Spain Fundación FFDIS in collaboration with Arrhythmia Network Technology SL.
- 14 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAI for the Prediction of Atrial Fibrillation or Atrial Tachycardia Episodes in Patients with Pacemakers (Preprint)
BACKGROUND Predictive medicine relies on algorithms to determine clinical treatments tailored to each patient’s individual characteristics. Predictive models based on AI have shown promise in identifying Atrial Fibrillation (AF) episodes; however, they rarely focus on short-term dynamic prediction. OBJECTIVE This study aims to evaluate the use of an AI model and remote monitoring data extracted from pacemaker devices to predict the onset or worsening of arrhythmias in the short term. METHODS This was an observational, prospective, multicenter study in which data from 314 patients were analyzed. A total of 65,243 data sequences were collected, of which 55,532 were used to train the algorithm. This model used 31-day records to predict whether the number of arrhythmic episodes increased, decreased, or remained the same in the following 14 days. RESULTS The sensitivity and specificity of the generated predictions were calculated from 9,711 prediction/observation pairs. The global sensitivity was 66.4% and specificity was 77.4%; with a sensitivity of 76.8% and specificity of 39.6% in patients with baseline arrhythmia; and a sensitivity of 39% and a specificity of 81% in patients without baseline arrhythmia. The analysis for the patient subgroup without prior history of AF yielded a 69% sensitivity and an 80% specificity. CONCLUSIONS This model was capable of predicting short-term increases or decreases in arrhythmic episodes with reasonable sensitivity and specificity, using data collected through remote monitoring of implantable devices. The model’s performance is expected to improve progressively as more data samples become available, including demographic and clinical records. CLINICALTRIAL Trial code: IA-Pacing Spain Fundación FFDIS in collaboration with Arrhythmia Network Technology SL.
- 4 September 2025
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 79 (3) , 280-282
Key messages on subclinical atrial fibrillation from the ARTESiA and NOAH trials
- 4 September 2025
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 79 (3) , 280-282
Key messages on subclinical atrial fibrillation from the ARTESiA and NOAH trials
- Open Access
- 31 August 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial
Aims: Apixaban was superior to aspirin for the prevention of stroke or systemic embolism in participants with subclinical atrial fibrillation (SCAF) in the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation trial. This was especially true for those with CHA2DS2-VASc score > 4. Understanding the cost-effectiveness of treating SCAF is important for decision-makers. Methods and results: Canadian, UK, German, and US direct healthcare costs [in 2023 US dollars (USD)] were applied to hospitalized events (including strokes and bleeds) and study drugs for all participants with a CHA2DS2-VASc score > 4 to determine the mean cost per participant during the trial (mean follow-up 3.5 years). A daily cost of $0.63, $0.11, $2.26, and $6.06 for apixaban in Canada, the UK, Germany, and the USA was used. If in-trial results were not cost-saving (below $0), the prospective plan was to perform a lifetime cost-effectiveness analysis using a Markov model and a willingness-to-pay of 50 000 USD per quality-adjusted life year (QALY). After considering the cost of study medication and clinical events over 3.5 years, apixaban was dominant (cost-saving and more effective) in Canada (−$2301) and the UK (−$902) but cost more in Germany and the USA ($600 and $1990, respectively). Over a lifetime, treatment with apixaban produced a net gain of 0.107 QALYs, but with costs in both Germany ($2623 more) and the USA ($9110 more), yielding an incremental cost-effectiveness ratio of $24 514 per QALY for Germany and $85 140 for the USA. Conclusion: In patients with SCAF and a CHA2DS2-VASc score > 4, apixaban is cost saving in Canada and the UK and cost-effective in Germany. Apixaban was not cost-effective in the USA under the base cost assumption but would be cost-effective at a daily cost of $4.35 and cost saving at $3.59.
- 31 August 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Open AccessCost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial
Aims: Apixaban was superior to aspirin for the prevention of stroke or systemic embolism in participants with subclinical atrial fibrillation (SCAF) in the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation trial. This was especially true for those with CHA2DS2-VASc score > 4. Understanding the cost-effectiveness of treating SCAF is important for decision-makers. Methods and results: Canadian, UK, German, and US direct healthcare costs [in 2023 US dollars (USD)] were applied to hospitalized events (including strokes and bleeds) and study drugs for all participants with a CHA2DS2-VASc score > 4 to determine the mean cost per participant during the trial (mean follow-up 3.5 years). A daily cost of $0.63, $0.11, $2.26, and $6.06 for apixaban in Canada, the UK, Germany, and the USA was used. If in-trial results were not cost-saving (below $0), the prospective plan was to perform a lifetime cost-effectiveness analysis using a Markov model and a willingness-to-pay of 50 000 USD per quality-adjusted life year (QALY). After considering the cost of study medication and clinical events over 3.5 years, apixaban was dominant (cost-saving and more effective) in Canada (−$2301) and the UK (−$902) but cost more in Germany and the USA ($600 and $1990, respectively). Over a lifetime, treatment with apixaban produced a net gain of 0.107 QALYs, but with costs in both Germany ($2623 more) and the USA ($9110 more), yielding an incremental cost-effectiveness ratio of $24 514 per QALY for Germany and $85 140 for the USA. Conclusion: In patients with SCAF and a CHA2DS2-VASc score > 4, apixaban is cost saving in Canada and the UK and cost-effective in Germany. Apixaban was not cost-effective in the USA under the base cost assumption but would be cost-effective at a daily cost of $4.35 and cost saving at $3.59.
- 17 July 2025
- Published by Elsevier in Medicina Clinica
- Vol. 165 (4) , 107104
Fibrilación auricular subclínica
- 17 July 2025
- Published by Elsevier in Medicina Clinica
- Vol. 165 (4) , 107104
Fibrilación auricular subclínica
- Top Cited PapersOpen Access
- 10 February 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (3) , 925-931
Artificial intelligence for direct-to-physician reporting of ambulatory electrocardiography
Developments in ambulatory electrocardiogram (ECG) technology have led to vast amounts of ECG data that currently need to be interpreted by human technicians. Here we tested an artificial intelligence (AI) algorithm for direct-to-physician reporting of ambulatory ECGs. Beat-by-beat annotation of 14,606 individual ambulatory ECG recordings (mean duration = 14 ± 10 days) was performed by certified ECG technicians (n = 167) and an ensemble AI model, called DeepRhythmAI. To compare the performance of the AI model and the technicians, a random sample of 5,235 rhythm events identified by the AI model or by technicians, of which 2,236 events were identified as critical arrhythmias, was selected for annotation by one of 17 cardiologist consensus panels. The mean sensitivity of the AI model for the identification of critical arrhythmias was 98.6% (95% confidence interval (CI) = 97.7–99.4), as compared to 80.3% (95% CI = 77.3–83.3%) for the technicians. False-negative findings were observed in 3.2/1,000 patients for the AI model versus 44.3/1,000 patients for the technicians. Accordingly, the relative risk of a missed diagnosis was 14.1 (95% CI = 10.4–19.0) times higher for the technicians. However, a higher false-positive event rate was observed for the AI model (12 (interquartile range (IQR) = 6–74)/1,000 patient days) as compared to the technicians (5 (IQR = 2–153)/1,000 patient days). We conclude that the DeepRhythmAI model has excellent negative predictive value for critical arrhythmias, substantially reducing false-negative findings, but at a modest cost of increased false-positive findings. AI-only analysis to facilitate direct-to-physician reporting could potentially reduce costs and improve access to care and outcomes in patients who need ambulatory ECG monitoring.
- 10 February 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (3) , 925-931
Top Cited PapersOpen AccessArtificial intelligence for direct-to-physician reporting of ambulatory electrocardiography
Developments in ambulatory electrocardiogram (ECG) technology have led to vast amounts of ECG data that currently need to be interpreted by human technicians. Here we tested an artificial intelligence (AI) algorithm for direct-to-physician reporting of ambulatory ECGs. Beat-by-beat annotation of 14,606 individual ambulatory ECG recordings (mean duration = 14 ± 10 days) was performed by certified ECG technicians (n = 167) and an ensemble AI model, called DeepRhythmAI. To compare the performance of the AI model and the technicians, a random sample of 5,235 rhythm events identified by the AI model or by technicians, of which 2,236 events were identified as critical arrhythmias, was selected for annotation by one of 17 cardiologist consensus panels. The mean sensitivity of the AI model for the identification of critical arrhythmias was 98.6% (95% confidence interval (CI) = 97.7–99.4), as compared to 80.3% (95% CI = 77.3–83.3%) for the technicians. False-negative findings were observed in 3.2/1,000 patients for the AI model versus 44.3/1,000 patients for the technicians. Accordingly, the relative risk of a missed diagnosis was 14.1 (95% CI = 10.4–19.0) times higher for the technicians. However, a higher false-positive event rate was observed for the AI model (12 (interquartile range (IQR) = 6–74)/1,000 patient days) as compared to the technicians (5 (IQR = 2–153)/1,000 patient days). We conclude that the DeepRhythmAI model has excellent negative predictive value for critical arrhythmias, substantially reducing false-negative findings, but at a modest cost of increased false-positive findings. AI-only analysis to facilitate direct-to-physician reporting could potentially reduce costs and improve access to care and outcomes in patients who need ambulatory ECG monitoring.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1747-1755
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA 2 DS 2 -VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted P interaction =0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63–1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban ( P trend =0.1). CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01938248.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1747-1755
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA 2 DS 2 -VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted P interaction =0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63–1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban ( P trend =0.1). CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01938248.
- Open Access
- 2 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (46) , 4902-4916
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
- 2 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (46) , 4902-4916
Open AccessAnticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
- 26 August 2024
- Published by Elsevier in Medicina Clinica
- Vol. 163 (10) , 496-502
Dispositivos digitales para la monitorización del ritmo cardiaco en pacientes con fibrilación auricular programados para cardioversión eléctrica ambulatoria
- 26 August 2024
- Published by Elsevier in Medicina Clinica
- Vol. 163 (10) , 496-502
Dispositivos digitales para la monitorización del ritmo cardiaco en pacientes con fibrilación auricular programados para cardioversión eléctrica ambulatoria